TITLE:
Small-for-size syndrome in living donor liver transplantation

AUTHOR(S):
Yagi, Shintaro; Uemoto, Shinji

CITATION:

ISSUE DATE:
2012-12

URL:
http://hdl.handle.net/2433/169675

RIGHT:
© 2012 The Editorial Board of Hepatobiliary & Pancreatic Diseases International. Published by Elsevier (Singapore) Pte Ltd.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.
Manuscript Type: Review article

Title: Small-for-size syndrome in living-donor liver transplantation

Running Title: SFSS in LDLT

Author: Shintaro Yagi, Shinji Uemoto

City: Kyoto, Japan

Author Affiliation: Department of Hepatobiliary, Pancreas and Transplant Surgery, Kyoto University Graduate School of Medicine, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto City, 606-8507, Japan (Shintaro Yagi and Shinji Uemoto)

Corresponding Author: Shintaro Yagi M.D., Ph.D. Department of Hepatobiliary, Pancreas and Transplant Surgery, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto city, Kyoto prefecture, Japan 606-8507, Phone: +81-75-751-4323, Fax: +81-75-751-4348, E-mail: shintaro@kuhp.kyoto-u.ac.jp

Funding: None

Ethical approval: Not needed

Competing interest: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
Abstract

When the graft volume is too small to satisfy the recipient’s metabolic demand ("small-for-size graft": SFSG), the recipient may thus experience “small-for-size syndrome” (SFSS). Because the occurrence of SFSS is determined by not only the liver graft volume but also a combination of multiple negative factors, the definitions of SFSG and SFSS are different in each institute and at each time.

In the clinical setting, surgical inflow modulation and maximizing the graft outflow are keys to overcoming SFSS. Accordingly, relatively smaller-sized grafts can be used with surgical modification and pharmacological manipulation targeting portal circulation and liver graft quality. Therefore, the focus of the SFSG issue is now shifting from how to obtain a larger graft from the living donor to how to manage the use of a smaller graft to save the recipient, considering donor safety to be a priority.
Introduction

In the last 20 years, the indications for living-donor liver transplantation (LDLT) have been successfully expanded from pediatric to adult cases. However, the use of grafts smaller than the native liver is unavoidable in cases of LDLT performed on adults. When the graft volume is too small to satisfy the recipient’s metabolic demand (“small-for-size graft”: SFSG), the recipient may thus experience “small-for-size syndrome” (SFSS). “SFSS” is characterized clinically by a combination of prolonged functional cholestasis, intractable ascites, and delayed functional recovery of both prothrombin time and encephalopathy (1-3). To avoid SFSG, the use of a larger-sized graft, such as the right lobe graft, is the standard strategy for adult-to-adult LDLT (4-7). However, although a right-lobe LDLT can provide an adequate graft size to meet the metabolic demands of most adult recipients, “SFSS” can be observed not only in “SFSG” recipients but also in larger-sized graft recipients (8-10). Therefore, the occurrence of SFSS is determined by not only the liver graft volume but also a combination of multiple negative factors. However, the procurement of a liver graft of greater volume imposes a greater risk on the donor because the remaining portion of the liver in the donor is smaller. Accordingly, the
criteria for SFSG in adult-to-adult LDLT have been revised recently at several institutes (2, 11). In other words, a relatively smaller-sized graft, such as the left lobe, can be used in adults with surgical manipulations aimed at reducing the portal venous pressure (PVP) and flow (PVF) (11, 12). Therefore, the focus of the SFSG issue is now shifting from how to obtain a larger graft from the living donor to how to manage the use of a smaller graft to save the recipient, considering donor safety to be a priority.

**Definition**

Kiuchi et al. (1) defined “SFSG” as a < 0.8% graft-to-recipient body weight ratio (GRWR). They reported that the use of “SFSG” leads to “SFSS,” including poor bile production, delayed synthetic function, prolonged cholestasis and intractable ascites, with subsequent septic complications and higher mortality. Sugawara et al. (13) suggested that a graft volume/standard liver volume ratio (GV/SLV) < 40% was associated with decreased survival and the prolonged recovery of liver function. At present, some institutes have established criteria for graft selection with a lower GRWR than before: GRWR > 0.8% (14, 15) or GRWR > 0.6% in combination with PVP control (11); these criteria show that the definition of “SFSG” has become lower in LDLT. Although there
has been no accepted definition of “SFSS” until now, several different definitions for SFSS or liver graft dysfunction have been given (3, 16-18) (Table 1).

Pathophysiology

I. Relative shortage of vital liver volume for life maintenance

The first possibility of the pathogenesis of poor prognosis in SFSG is the relative shortage of hepatic parenchymal cells. Previous clinical analyses have suggested that a normal liver can tolerate a partial hepatectomy to 25 - 27 % of the residual volume (19-21).

II. Portal hypertension: shear stress

The characteristic microscopic findings of SFSS, including hepatocyte ballooning and cholestasis, are thought to be due to microcirculatory disturbances (22). Many experimental and clinical studies (12, 23-28) suggest that elevated PVP (shear stress) forms the central pathogenesis of SFSS. A persistent elevation of the PVP in the graft, which is attributable to hyperdynamic splanchnic circulation (29) and limited accommodation of the graft, causes sinusoidal endothelial cell injury (25) and the release of deleterious mediators (30), which ultimately lead to serious graft injury. Shear stress
also leads to an imbalance in the expression of intragraft vasoregulatory genes, such as endothelin-1 and nitric oxide (31). Microcirculatory disorders in SFSG will eventually result in graft dysfunction (32).

III. Arterial hypoperfusion

The role of arterial hypoperfusion in SFSS is less well studied as it is secondary to portal hyperperfusion. Low hepatic artery flow is considered to be due to a homeostatic mechanism known as the hepatic arterial buffer response (33). In states of extreme portal hyperperfusion, such as those observed in SFSG, an exaggerated hepatic arterial buffer response may contribute to ischemic injury, ischemic cholangitis, and cholestasis.

IV. Intestinal mucosal injury

We demonstrated that the intestinal mucosa was severely damaged with portal hypertension following SFSG liver transplantation in swine (26). Several experimental studies (34-39) have revealed that portal hypertension in liver cirrhosis can increase bacterial translocation by inducing congestion and edema of the intestine. Accordingly, bacterial translocation could be developed in an SFSG-transplanted recipient due to the elevation of mucosal permeability, which is compatible with the clinical aspect of a
higher postoperative infection rate in SFSS (40).

V.  Liver regeneration

After extensive hepatectomy or segmental liver transplantation with an SFSG, liver regeneration is essential for patient survival. Liver regeneration is a highly complex and organized process that has been shown to involve the actions of a number of cytokines and growth factors, such as hepatocyte growth factor (HGF) (41), transforming growth factor-α (42), epidermal growth factor (43), hepatocyte growth factor activator (HGFA) (44) and vascular endothelial growth factor (VEGF) (45). Shear stress is well defined as a putative trigger mechanism for liver regeneration (46-48). During the first week after a partial liver transplantation, the partial liver graft regenerates quickly, up to approximately 80-100% compared with the standard liver volume (47). Ninomiya et al. (49) showed that SFSGs regenerated faster and were associated with significantly higher peripheral HGF levels one day after LDLT than non-SFSGs. Many previous studies have suggested that the elevation of PVF or shear stress induces liver regeneration and that insufficient PVF induces hepatic atrophy and liver failure (50-57). Portal hyperperfusion can promote liver regeneration only if it is limited to a certain extent. Hessheimer et al.
(58) suggested that the liver graft requires PVF superior to its normal baseline value for liver regeneration and that a calibrated portocaval shunt (PCS) that maintains the PVF at twice its baseline value produces a favorable outcome after swine liver transplantation with a 30% SFSG.

**Clinical Factors influencing SFSS**

**I. Quality of the graft**

Factors regulating liver graft compliance would be the potential definition of the graft quality, such as donor age, steatosis, and ischemic injury. Other unknown factors may also precipitate SFSS.

a. *Ischemic injury*

Both warm (59) and cold ischemia (60) have been shown to impair regeneration after partial liver transplantation. The difference in the essential liver volume after the operation between an extended hepatectomy and partial liver transplantation may owe much to the existence of this issue.

b. *Steatosis*
A steatotic liver graft from a deceased donor with a longer cold ischemic time is well known to be associated with poor graft function and survival. A previous study revealed that steatotic liver grafts are related to the increased susceptibility to ischemia-reperfusion injury (61, 62), including impaired graft microcirculation and PVF, increased hepatocellular damage observed serologically and histologically, increased pro-inflammatory cytokine production, and decreased ATP concentration. However, in an LDLT setting with a shorter cold ischemic time compared with a deceased donor graft, Hayashi et al. (63) reported that early graft function after LDLT was similar in mild and moderate steatosis but that severe steatosis was significantly associated with poor graft function and survival. In any case, SFSS is determined by a combination of multiple negative factors, and steatotic liver grafts should be avoided if the graft volume is small.

c. Donor age

Moon et al. (64) have shown that an older donor age affects graft prognosis only when combined with an SFSG. Ikegami et al. (65) reported that the function and regeneration of the allografts from older donors in LDLT are worse than those of their younger counterparts. Tanemura et al. also (66) reported that donor age (≥ 50 years) was
independently correlated with impaired remnant liver regeneration at 6 months in right lobe LDLT.

d. Congestion

The magnitude of the impact of tissue congestion caused by interrupted venous drainage is highly variable among grafts. Severe congestion in the anterior segment has been reported to occur in right lobe grafts without the middle hepatic vein, which leads to massive ascites and graft dysfunction (8).

II. Perioperative recipient related factors

A. Preoperative recipient status:

With respect to the maintenance of the initial graft function, the post-transplant metabolic and synthetic demands in recipients with severely damaged liver function (hyperbilirubinemia, coagulopathy) and a pre-operative deteriorated general condition (renal dysfunction, septic state, etc.) aggravate the metabolic function of the graft (1, 67).

Furthermore, the liver grafts may be insufficiently functional for the excessive metabolic and synthetic demands of high-risk recipients, including their reduced metabolic and synthetic capacities. Therefore, a pre-operative deteriorated condition with a high model
for endstage liver disease (MELD) score may impair the function of the graft, leading to
graft dysfunction, graft failure and eventually multiple organ failure, especially in SFSG.

Yoshizumi et al. (68) reported that a larger graft is necessary if the donor age is > 50 years
and the MELD score is >20. Accordingly, Ikegami et al. (69) recommended that high-risk
patients should receive a larger, younger graft to minimize the risk of SFSS.

B. Portal circulation (Pressure and Flow):

After LDLT, Ogura et al. (70) demonstrated that a PVP <15 mmHg is associated with
good patient outcome in a retrospective clinical analysis: patients with a PVP <15 mmHg
demonstrated a better 2-year survival (93.0%) than patients with a portal pressure ≥15
mmHg (66.3%).

Hessheimer et al. (58) reported that the PV-inferior vena cava (IVC) pressure gradient and
PVP were significantly higher in SFSG liver transplantation in swine and that the PCS
decreased both the PVP and PV-IVC pressure gradients. However, Ogura et al. (12)
reported in a retrospective clinical study of LDLT that although the PV-IVC pressure
gradient was higher in the group with the higher PVP, there were no significant
differences in the 1- and 3-year survival rates when they divided and analyzed their study
group by low (< 9 mm Hg) and high (≥ 9 mm Hg) PV-IVC pressure gradients. Further experiments or clinical trials of SFSG are necessary to determine whether the PVP or PV-IVC pressure gradient is more significant for SFSG.

In clinical research, we showed that a high compliance (PVF/PVP) graft in which the PVF can be maintained at a high level despite a low PVP is a good graft for postoperative liver graft function (71). The optimal portal venous circulation for the liver graft could depend on the graft size and quality.

**Intervention to avoid SFSS**

(1) **Graft selection: increase the graft volume and maximize the outflow**

After the concept of “SFSS” had been reported, the graft type shifted from the left side to the right side of the liver to increase the liver graft volume. Dual graft liver transplantation was also proposed when two donors were available in some institutes (72, 73).

Regarding the usage of a “right-side graft”, to avoid the development of a congested area in the anterior segment, some institutes have preferred to use a “with MHV graft”. Fan et al. chose an extended right-lobe graft with the MHV (74). In contrast, the additional
venous reconstruction of the anterior segment with an interposition vein graft has been adopted by Lee et al. (8). The reconstruction of the segment V and VIII branches using jump grafts has been reported (75). In our institute, we have performed the venous reconstruction of the anterior segment together with an anterior patch plasty of the hepatic vein using the native portal vein to maximize the liver graft outflow (76).

We reported that the compliance per unit of graft weight in left-lobe grafts is higher than in right lobe grafts without MHV in LDLT (71). Shimada et al. (77) also reported that left-lobe grafts are a feasible option for LDLT because the outflow of the left-lobe graft is considered superior to that of the right-lobe graft and in the case of right-locale grafts without the MHV, hepatic venous drainage is one of the most critical problems.

Accordingly, beginning in December 2007, our institution has actively selected the left-locale graft for use in LDLT to maximize the graft outflow and minimize the risks to the healthy donor.

(2) Portal inflow modulation

Boilot et al. (78) first reported a case in which a recipient-transplanted SFSG with a GRWR of 0.61% was successfully treated by the reduction of PVP with a mesocaval
shunt. Thereafter, several surgeons have reported the successful treatment of SFSG by surgical manipulations to reduce the PVP and PVF with a splenic arterial ligation (28), PCS (27, 79, 80) or splenectomy (12, 81-83) in clinical and animal studies (84, 85). However, because the diversion of portal inflow can lead to liver necrosis or atrophy, an adequate PVF is essential for liver regeneration (26, 52, 58). We reported that an SFSG-transplanted swine with a large PCS could not survive more than 5 days after liver transplantation, with its autopsy showing massive hepatic necrosis. A large PCS, which would greatly reduce the PVF and therefore result in graft failure, should be avoided (26). Therefore, in our institution, a splenectomy is performed first to decrease the PVP (< 15 mmHg), and all large collaterals are ligated to prevent the steal phenomenon in some situations, which decrease the compliance after LDLT (such as rejection) (83).

(3) Other interventions

In experimental research, several pharmacological interventions have been reported to improve the survival after SFSG, including the portal infusion of prostaglandin E1 (86), granulocyte colony-stimulating factor (87), endothelin A receptor antagonist (31), redox factor-1 (88), somatostatin (89), and hyperbaric oxygen treatment (90) to promote liver
regeneration or reduce ischemia-reperfusion injury after an SFSG liver transplantation.

(4) Organ preservation

Newly developed preservation solutions, such as POLYSOL (32), activated protein C (91) in preservation solution, and cold preservation using retrograde nitric oxide with oxygen administration, for SFSG liver transplantation (92) were reported to recondition the liver graft viability and promote liver regeneration in rats.

Conclusion

SFSG has become an issue again with respect to pursuing donor safety. Because the occurrence of SFSS is determined by not only the liver graft volume but also a combination of multiple negative factors, we should manage all risk factors and make efforts to improve the outcomes associated with SFSG.
References


11. Kaido T, Mori A, Ogura Y, Hata K, Yoshizawa A, Iida T, et al. Lower limit of the graft-to-recipient weight ratio can be safely reduced to 0.6% in adult-to-adult
living donor liver transplantation in combination with portal pressure control.


Distinct intragraft response pattern in relation to graft size in liver transplantation. 

endothelin/nitric oxide balance determines small-for-size liver injury after 

Improved preservation and microcirculation with POLYSOL after partial liver 

33. Smyrniotis V, Kostopanagiotou G, Kondi A, Gamaletsos E, Theodoraki K, 
Kehagias D, et al. Hemodynamic interaction between portal vein and hepatic 
artery flow in small-for-size split liver transplantation. Transpl Int. 

34. Hashimoto N, Ohyanagi H. Effect of acute portal hypertension on gut mucosa. 


42. Kan M, Huang JS, Mansson PE, Yasumitsu H, Carr B, McKeehan WL.


44. Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N.
Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem. 1993;268:10024-10028.


60. Selzner N, Selzner M, Tian Y, Kadry Z, Clavien PA. Cold ischemia decreases liver regeneration after partial liver transplantation in the rat: A...


2000;70:1703-1707.


85. Pouyet M, Paquet C. Effect of mesocaval shunt on survival of small-for-size liver

Effect of intraportal infusion to improve small for size graft injury in living donor
adult liver transplantation. Transplant international : official journal of the


hepatic regeneration with reduced injury by redox factor-1 in a rat small-sized

phase shear stress by somatostatin improves small-for-size liver graft survival.
Liver transplantation : official publication of the American Association for the
Study of Liver Diseases and the International Liver Transplantation Society.


Table 1: Proposed definitions of small-for-size syndrome

<table>
<thead>
<tr>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Small-for-size dysfunction (SFSD)</strong></td>
</tr>
<tr>
<td>Dysfunction* of a ‘small’ partial liver graft (GRWR &lt; 0.8%) during the first postoperative week after the exclusion of other causes***.</td>
</tr>
<tr>
<td><strong>Small-for-size non-function (SFSNF)</strong></td>
</tr>
<tr>
<td>Failure** of a ‘small’ partial liver graft (GRWR &lt; 0.8%) during the first postoperative week after the exclusion of other causes***.</td>
</tr>
<tr>
<td><strong>Small for size syndrome</strong></td>
</tr>
<tr>
<td>Prolonged cholestatis (T.Bil &gt;10 mg/dL on POD14) and intractable ascites (ascites &gt; 1 L on POD 14 or &gt;0.5 L on POD 28).</td>
</tr>
<tr>
<td><strong>Small for size syndrome</strong></td>
</tr>
<tr>
<td>T.Bil &gt; 10 mg/dL (and continuing to increase) after POD 7, PT-INR &gt; 1.5 and ascites &gt; 2 L, excluding mechanical/technical problems.</td>
</tr>
<tr>
<td><strong>Delayed functional hyperbilirubinemia (DFH)</strong></td>
</tr>
<tr>
<td>with T.Bil &gt; 20 mg/dL For &gt; seven consecutive days after POD 7, excluding technical, immunological and hepatitis factors.</td>
</tr>
</tbody>
</table>

* Graft dysfunction = the presence of two of the following on three consecutive days: bilirubin > 100 lmol/l, INR > 2, encephalopathy grade 3 or 4.

** Graft failure = re-transplantation or death of recipient.

*** Exclusion criteria: technical (e.g. arterial or portal occlusion, outflow congestion, bile leak), immunological (e.g. rejection), infectious (e.g. cholangitis, sepsis).